Subscribe To
VERA / Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
Content Topics
VERA
Therapeutics
Selected
Present
Interim
Phase
Data
Mau868
Kidney
Transplant
Patients
Late breaker
American
Congress
Stock
VERA News
By Zacks Investment Research
October 18, 2023
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this more_horizontal
By Zacks Investment Research
October 17, 2023
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combi more_horizontal
By Zacks Investment Research
October 16, 2023
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround
Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong ag more_horizontal
By GlobeNewsWire
October 13, 2023
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase more_horizontal
By Zacks Investment Research
August 15, 2023
What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock
Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This mi more_horizontal
By Seeking Alpha
July 4, 2023
Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target
Vera Therapeutics revealed 36-week efficacy and safety findings of its Phase IIb ORIGIN clinical study of atacicept for IgAN at the 60th European Rena more_horizontal
By Seeking Alpha
July 3, 2023
Vera: Repurposed Molecule Program Does Not Impress
Vera Therapeutics, Inc. is trying to develop an old molecule it licensed from Merck & Co., Inc. Trials conducted years earlier produced unimpressive r more_horizontal
By The Motley Fool
June 20, 2023
Why Shares of Vera Therapeutics Jumped Tuesday
The company's lead therapy, Atacicept, is faring well in a phase 2b trial. Vera Therapeutics is already recruiting patients for a phase 3 trial for At more_horizontal